Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) reported Q1 2026 results and key pipeline milestones. License and collaboration revenue was $2.2 million, with a net loss of $65.5 million ($0.75/share). Cash and equivalents total about $90 million, with a runway projected into 2029 supported by a $35 million senior notes financing and a planned $5 million equity investment from Oberland Capital.
Clinically, LCA5 showed six‑month pediatric gains of ~1.5 log unit in cone sensitivity and FDA RDEP acceptance, with a pivotal Phase 3 trial preparing to dose in Q4 2026. BEST1 Cohort 1 topline data are expected in September 2026, and RDH12, MERTK, and RHO programs are slated to enter the clinic over the next 12–18 months.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Q1 2026 license and collaboration revenue of $2.2 million
- Cash and cash equivalents of about $90 million after Oberland funding
- Financing includes $35 million senior secured notes plus $5 million equity
- Cash runway projected to fund operations into 2029
- LCA5 pediatric cohort shows ~1.5 log unit cone sensitivity gains at six months
- LCA5 program accepted into FDA Rare Disease Evidence Principles program
- Pivotal Phase 3 OPGx-LCA5 dosing expected to begin in Q4 2026
- BEST1 Phase 1/2 Cohort 1 enrollment completed with data expected September 2026
- RDH12 program expected to enter the clinic in Q4 2026 with external funding support
- MERTK clinical development underway with consortium-led funding
- RHO program expected to enter the clinic in 2027 after supportive large-animal data
Negative
- Q1 2026 revenue declined to $2.2 million from $4.4 million year over year
- R&D expenses increased to $10.6 million from $8.0 million year over year
- Net loss widened to $65.5 million from $8.2 million year over year
- Significant non-cash expense from fair value change in warrant liabilities
- Company remains loss-making with reliance on external financing
News Market Reaction – IRD
On the day this news was published, IRD gained 1.17%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.2% during that session. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $369.86M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Full-year 2025 results | Positive | +1.7% | Reported 2025 results, cash $45.1M, financing and multiple clinical milestones. |
| Nov 12 | Q3 2025 earnings | Positive | -2.5% | Positive OPGx-LCA5 data, RMAT meeting, solid cash plus revenue and loss update. |
| Aug 13 | Q2 2025 earnings | Positive | +7.3% | RMAT for OPGx-LCA5, Phase 3 phentolamine success, higher revenue and non-dilutive funding. |
| May 15 | Q1 2025 earnings | Positive | +0.0% | Positive 12‑month OPGx-LCA5 data, advancing OPGx-BEST1, strong cash from offerings. |
| Mar 31 | Full-year 2024 results | Negative | -2.8% | 2024 revenue declined and net loss widened despite pipeline progress post‑acquisition. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and corporate updates have generally produced modestly positive or mixed reactions, with most events aligning with the underlying news tone.
Across the last five earnings/financial updates from Mar 2025 through Mar 2026, Opus Genetics consistently paired financials with gene therapy milestones. Cash balances increased from the low- to mid-$30M range to $45.1M by year-end 2025, supplemented by equity financings. Clinically, OPGx-LCA5 advanced with FDA RMAT designation and pivotal planning, while OPGx-BEST1 moved into and through early clinical stages. Market reactions were often modest, with one stronger positive move after Q2 2025 results.
Key Terms
phase 1/2 trial medical
pivotal phase 3 trial medical
aav vector medical
rare disease evidence principles (rdep) regulatory
priority review vouchers regulatory
senior secured notes financial
topline data medical
run-in period medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET
Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026
LCA5 Accepted to FDA’s Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal Trial
RDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 Months
Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals
and Opportunities for Priority Review Vouchers
RESEARCH TRIANGLE PARK, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.
“With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics is entering a defining stretch where we believe our precision targeted approach can reshape what’s possible for patients with inherited retinal diseases,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “Our upcoming BEST1 Cohort 1 clinical data and June R&D Science Forum will provide key opportunities to showcase the depth and maturity of our science and pipeline. Backed by a strong balance sheet and disciplined capital strategy, we are well-positioned to advance our lead programs toward pivotal trials, and accelerate our earlier‑stage RDH12, MERTK, and RHO programs into the clinic.”
Pipeline Updates
Research & Development (R&D) Science Forum
- Opus Genetics plans to host an R&D Science Forum on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET, with management and key opinion leaders (KOLs) highlighting earlier-stage gene therapy programs entering clinical testing and IRD global market opportunities. Registration for the event will be available on the Events page of the Opus Genetics website.
OPGx-BEST1
- Enrollment completed in Cohort 1 of the Phase 1/2 trial (BIRD-1) including participants with both dominant and recessive forms of BEST disease, with the final participant scheduled for dosing this month.
- Baseline demographics were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting with the related poster presentation available on the Publications & Presentations page of the Opus Genetics website. Additionally, a slide presentation and video summary recording titled “OPGx-BEST1 Cohort 1 Baseline Demographics and Key Endpoints for IRDs” are provided on the IR Presentations page of the Opus Genetics website.
- Opus Genetics expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial in September 2026.
OPGx-LCA5
- Positive six-month pediatric cohort data was presented at ARVO 2026; robust and consistent improvements were observed in cone-mediated function with average gains of approximately 1.5 log unit in cone sensitivity, reaching normal ranges after a single dose. Improvements were also observed in objective measures, visual acuity, and functional vision. The therapy was well tolerated, with most adverse events anticipated, mild, and not related to OPGx-LCA5.
- The U.S. Food and Drug Administration (FDA) granted acceptance of the LCA5 program into the Rare Disease Evidence Principles (RDEP) program, which is designed to provide guidance on the types of evidence that can be used to demonstrate substantial evidence of effectiveness, including the potential use of a single adequate and well-controlled study supported by confirmatory evidence.
- Recruitment is ongoing in the run-in period for the pivotal Phase 3 trial. In parallel, the clinical and commercial batch of drug product is being manufactured. Dosing with OPGx-LCA5 is expected to start in the fourth quarter of 2026.
OPGx-RDH12
- OPGx-RDH12 is being developed to deliver a functional RDH12 gene to photoreceptors using an AAV vector.
- This program is expected to enter the clinic in the fourth quarter of 2026. Funding is supported by the RDH12 Alliance.
OPGx-MERTK
- OPGx-MERTK is being developed for retinal degeneration caused by mutations in the MERTK gene, which plays a critical role in phagocytosis of photoreceptor outer segments by RPE cells.
- Clinical development activities are underway. Funding is supported by a consortium led by Abu Dhabi’s Healthcare Research and Innovation Fund.
OPGx-RHO
- Preclinical data presented at ARVO 2026 and the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2026 provided safety and efficacy data on the use of OPGx-RHO in two large animal models of autosomal-dominant retinitis pigmentosa (adRP). This preclinical work was co-funded by the Foundation Fighting Blindness and the National Institutes of Health.
- This program is expected to enter the clinic in 2027.
Recent Medical Presentations
- ARVO 2026 Annual Meeting:
- “Restoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5”
- “Preliminary Results from Adult Participant in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for ARB and BVMD Due to BEST1 Mutations”
- “Development of Cell-Based Expression and Functional Potency Assays for OPGx-BEST1 Gene Therapy”
- “Nonclinical Efficacy and Toxicity Study of GMP-Grade Vector OPGx-RHO (Scaav2/5-RHO820-Shrna820) Delivered by Subretinal Injection in a Canine Model of RHO-adRP”
- “Therapeutic Efficacy of a Mutation-Independent AAV Knockdown and Replacement Approach in a Swine Animal Model of Autosomal-Dominant Retinitis Pigmentosa (adRP)”
- Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2026: “Safety and Efficacy of OPGx-RHO Silence-and-Replace Gene Therapy for RHO-adRP: Evidence Across Two Large Animal Models”
- The Macula Society Annual Meeting: “Preliminary Results from Sentinel Patient in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations”
- Asia-Pacific Academy of Ophthalmology Congress (APAO): “Gene Therapy for BEST1 Inherited Retinal Disease”
- Advanced Therapies Week: “Building Scalable Viral Vector Manufacturing Models”
Financial Results for the First Quarter Ended March 31, 2026
Cash Position: As of March 31, 2026, Opus Genetics had cash and cash equivalents of
Revenue: License and collaborations revenue totaled
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss for the quarter ended March 31, 2026 was
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to cash runway and future financing availability, potential future funding under the Oberland facility, potential product approvals, and Priority Review Voucher opportunities, the clinical development, clinical results, preclinical data and future plans for Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
| Opus Genetics, Inc. Condensed Consolidated Balance Sheets (in thousands, except share amounts and par value) | |||||||
| As of | |||||||
| March 31, 2026 | December 31, 2025 | ||||||
| Assets | (Unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 59,959 | $ | 45,091 | |||
| Accounts receivable | 1,731 | 1,995 | |||||
| Contract assets and unbilled receivables (Note 10) | 984 | 1,170 | |||||
| Prepaids and other current assets | 3,927 | 1,788 | |||||
| Total current assets | 66,601 | 50,044 | |||||
| Property and equipment, net | 186 | 199 | |||||
| Total assets | $ | 66,787 | $ | 50,243 | |||
| Liabilities, convertible preferred stock and stockholders’ (deficit) equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 4,422 | $ | 3,293 | |||
| Accrued expenses | 4,918 | 4,488 | |||||
| Total current liabilities | 9,340 | 7,781 | |||||
| Warrant liabilities | 77,349 | 25,985 | |||||
| Funding agreement, related party | 1,198 | 1,129 | |||||
| Total liabilities | 87,887 | 34,895 | |||||
| Commitments and contingencies (Note 3 and Note 9) | |||||||
| Series B preferred stock, par value | 24,736 | — | |||||
| Stockholders’ (deficit) equity: | |||||||
| Preferred stock, par value | — | — | |||||
| Common stock, par value | 7 | 7 | |||||
| Additional paid-in capital | 208,281 | 203,930 | |||||
| Accumulated deficit | (254,124 | ) | (188,589 | ) | |||
| Total stockholders’ (deficit) equity | (45,836 | ) | 15,348 | ||||
| Total liabilities, convertible preferred stock and stockholders’ (deficit) equity | $ | 66,787 | $ | 50,243 | |||
| Opus Genetics, Inc. Condensed Consolidated Statements of Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) | |||||||
| For the Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| License and collaborations revenue | $ | 2,157 | $ | 4,370 | |||
| Operating expenses: | |||||||
| Research and development | 10,577 | 7,953 | |||||
| General and administrative | 5,944 | 6,346 | |||||
| Total operating expenses | 16,521 | 14,299 | |||||
| Loss from operations | (14,364 | ) | (9,929 | ) | |||
| Fair value change in warrant liabilities | (51,364 | ) | 2,805 | ||||
| Financing costs | (582 | ) | (1,372 | ) | |||
| Interest expense | (69 | ) | — | ||||
| Other income, net | 844 | 302 | |||||
| Loss before income taxes | (65,535 | ) | (8,194 | ) | |||
| Benefit (provision) for income taxes | — | — | |||||
| Net loss | (65,535 | ) | (8,194 | ) | |||
| Other comprehensive loss, net of tax | — | — | |||||
| Comprehensive loss | $ | (65,535 | ) | $ | (8,194 | ) | |
| Net loss per share: | |||||||
| Basic and diluted | $ | (0.75 | ) | $ | (0.24 | ) | |
| Number of shares used in per share calculations: | |||||||
| Basic and diluted | 86,891,352 | 33,884,920 | |||||
Source: Opus Genetics, Inc.
